Publications by authors named "Louis Boismoreau"
Article Synopsis
- The study aimed to evaluate the incidence of atrial fibrillation (AF) linked to 19 anticancer drugs used alone in clinical trials, focusing on how common AF is among cancer patients receiving these treatments.
- Researchers analyzed 191 clinical trials involving 16 anticancer drugs and found that AF rates varied from 0.26 to 4.92 cases per 100 person-years, with the highest rates associated with ibrutinib, clofarabine, and ponatinib.
- The findings highlight that AF is a significant concern in patients undergoing treatment with these drugs, suggesting the need for better monitoring procedures in clinical trials for drugs known to cause higher AF rates.
Background: Cyclin dependent kinase inhibitors (CdK4/6i) changed the course of hormone receptor positive (HR+) HER2 negative (HER2-) metastatic breast cancer (mBC). To date, no factors have been shown to predict response to CdK4/6i. Neutrophil-to-lymphocyte ratio (NLR), an indicator of the host systemic inflammatory response, is an independent prognostic factor for survival in cancers.
View Article and Find Full Text PDF